Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
New Stage 4 Colon Cancer Alternative Cancer Treatment andNatural Cancer treatment using Natural Killer Cells for ColonCanc...
That being said, new immunotherapy treatments are bringing new hope as they delivera key part of the treatment puzzle - al...
malignancies.8,9 While NKs and NKTs are commonly found circulating in the body inminimal amounts, they possess the ability...
operated stage I-III diseases, preoperative NK cell activity of 20 percent or lesscorrelated with poor survival. This lowe...
The vaccine(s) is compiled by growing a patient’s own antitumor immune cells into thebillions. These cells are then analyz...
cancer cells in the laboratory, and then subsequently re-infused into the patient.Heralded by scientific research and clin...
Upcoming SlideShare
Loading in …5
×

New Stage 4 Colon Cancer Alternative Cancer Treatment and Natural Cancer treatment using Natural Killer Cells for Colon Cancer

1,600 views

Published on

http://www.envita.com/ Stage 4 Colon Cancer has 5 stage.Stage 4 colon Cancer is the a lot of exhausted affliction stage.stage 4 colon Cancer has beat to abutting lymph nodes and added locations of the body. Common destinations accoutrement the alarmist and the lungs.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

New Stage 4 Colon Cancer Alternative Cancer Treatment and Natural Cancer treatment using Natural Killer Cells for Colon Cancer

  1. 1. New Stage 4 Colon Cancer Alternative Cancer Treatment andNatural Cancer treatment using Natural Killer Cells for ColonCancerNew Stage 4 Colon Cancer Alternative Cancer Treatment andNatural Cancer treatment using Natural Killer Cells for ColonCancerImmunotherapy: Powerful New Weapon Against Stage 4 Colon and Stage 4Cancers With Advanced Natural Cancer Treatment and Alternative CancerTreatmentImmunotherapy is undisputedly an innovative premier medical strategy that relies on thehuman immune system to conquer disease. Theoretically over the last 30 odd years,extensive research conducted by teams of physicians and scientists has proven thatthis venue is clinically successful for a wide range of diseases. Advances in adoptiveimmunotherapy, which concentrates on the expansion and infusion of specific disease-fighting white blood cells in patients, have boosted this science to peak performance interms of being an effective treatment for viral diseases, colon cancer, and even stage 4cancer types.As time goes by, we can expect to see the importance of immunotherapy grow,particularly in late stage colon cancer, where patients experience metastasis andtargeting the cancer as it spreads becomes even more important. To date, stage 4colon cancer is not much more than chemo and radiation. The statistics are so grimthat renowned care providers would not dare report survival data beyond the first coupleof years as it is more sobering than promising.
  2. 2. That being said, new immunotherapy treatments are bringing new hope as they delivera key part of the treatment puzzle - along with better results and quality of life forpatients.Stage 4 Colon Cancer: Natural Killer and Natural Killer T Cells - TypicallyDepressed in Stage 4 Colon Cancer Patients Data to Support Alternative CanerTreatment and Natural Cancer TreatmentIn a study1 of 102 colorectal cancer patients undergoing resections; 18 of them hadrecurrences within two years of surgery. In all 18, there was significant evidence of"significantly lower preoperative NK cytotoxicity than disease-free patients." Lowpreoperative NK cytotoxicity was predictive of recurrence in this cohort of patients. 1And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer inaddition to 149 healthy controls, it was observed that Natural Killer levels in coloncancer patients were significantly lower than those of the healthy control group.Moreover, it has been shown3 that untreated patients with colon cancer havesuppressed Natural Killer and Lymphokine-activated killer cells - particularly in latestage patients. These patients were also found to have compromised interferon-gammaproducing activities.NK cell activity serves as a strong prognostic factor for distant metastasis followingsurgery for colon cancer. In a study4 with 140 colon cancer patients in curativelyoperated stage I-III diseases, preoperative NK cell activity of 20 percent or lesscorrelated with poor survival. This lower NK activity was also associated with distantmetastases, while attenuated NK cell activity was a significant parameter for predictingdistant metastasis following curative surgery.Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients aresignificantly related to overall survival, progression-free survival, and response rate.Moreover, it has also been observed that colon cancer patients who are 6 to 12 monthsafter tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - significantly higher than those found in age-matchedcontrols of healthy individuals.Sadly, conventional medicine has virtually ignored this type of immunotherapy ... untilnow.Astounding Progress in Treating Stage 4 Colon Cancer and Other Stage 4Cancers with Proprietary Immunotherapy Breakthrough Alternative CancerTreatment and Natural Cancer TreatmentRecently, a bevy of researchers have touted the successful clinical use of natural killercells (NKs) and natural killer T cells (NKTs) in treating patients with various
  3. 3. malignancies.8,9 While NKs and NKTs are commonly found circulating in the body inminimal amounts, they possess the ability to identify and kill both tumor cells and virallyinfected cells, and are a major initial defense of our immune system. Without question,patients with colon cancer and stage 4 cancers are often found to be deficient inproduction of these powerful cells. Over the last 20 years, a number of studies havedescribed NK dysfunction in colon cancer patients.10-12Specifically, NKs from these patients show a lesser ability to destroy tumor cells inlaboratory tests than NKs from healthy patients.10-12 NKs from later stage patientswere dramatically more dysfunctional compared to early stage patients with nometastases.10,11 Further, NKs from patients with more advanced disease had animpaired response to interferon, a major growth factor for NK cells.10 T lymphocytesfrom such patients also do not respond well to stimulatory factors.12 The amount andfunction of NKT cells have also been under investigation in colon cancer patients.13NKT numbers in these patients were significantly reduced compared to healthy controlsand patients with other cancer types; further, NKTs in these patients were lessresponsive to short-term stimulation, yet were still capable of substantial expansion.13Such research cumulatively suggests that colon cancer patients experience an immunesuppression that worsens as disease progresses. However, cells with anti-tumoractivity can indeed be expanded from these patients for worthy use in clinicalimmunotherapy regimens.It is important to note that expansion of natural killer cells is not the same, in process oreffect, as taking a product or providing an intravenous nutrient or substance to increaseNK cells in the patient. Such methods are far inferior to the targeted, expansion method.Natural Killer and Natural Killer T Cells are Depressed in Stage 4 Colon CancerPatients the data is clear Alternative Cancer Treatment and Natural CancerTreatment Provides Important OptionsIn a study1 of 102 colorectal cancer patients undergoing resections; 18 of them hadrecurrences within two years of surgery. In all 18, there was significant evidence of"significantly lower preoperative NK cytotoxicity than disease-free patients." Lowpreoperative NK cytotoxicity was predictive of recurrence in this cohort of patients.1And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer inaddition to 149 healthy controls, it was observed that Natural Killer levels in coloncancer patients were significantly lower than those of the healthy control group.Moreover, it has been shown3 that untreated patients with colon cancer havesuppressed Natural Killer and Lymphokine-activated killer cells - particularly in latestage patients. These patients were also found to have compromised interferon-gammaproducing activities.NK cell activity serves as a strong prognostic factor for distant metastasis followingsurgery for colon cancer. In a study4 with 140 colon cancer patients in curatively
  4. 4. operated stage I-III diseases, preoperative NK cell activity of 20 percent or lesscorrelated with poor survival. This lower NK activity was also associated with distantmetastases, while attenuated NK cell activity was a significant parameter for predictingdistant metastasis following curative surgery.Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients aresignificantly related to overall survival, progression-free survival, and response rate.Moreover, it has also been observed that colon cancer patients who are 6 to 12 monthsafter tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - significantly higher than those found in age-matchedcontrols of healthy individuals.This data begs the question why are NK cells and immune system considered vastlymore important to conventional cancer treatment protocols? It was questions like thisone that led Envita to develop a proprietary new treatment.Envita Leads the Field in Stage 4 Colon Cancer and Stage 4 Cancer- TargetedImmunotherapy Latest In Alternative Cancer Treatment and Natural CancerTreatmentMultitudes of published studies have demonstrated the effects of adoptive immunetherapy in cancer patients. Envitas renowned medical team assessed the best of thesestudies and focused on the strengths and weaknesses of each. Their findingsestablished a protocol that incorporates only the best procedures for the expansion andapplication of cells as a powerful immunotherapy. Our protocols are based on the mostrecent published research in the field, from some of the most prestigious hospitals anduniversities in the nation and around the world. However, our treatment has beenspecially designed to deal specifically with colon cancer and stage 4 cancer patientsimmune systems. And the sooner this treatment method is administered to the patient,the quicker improvements are experienced throughout the whole of their treatment.Envitas Two-fold Stage 4 Colon Cancer and Stage 4 Cancer ImmunotherapyAlternative Cancer Treatment and Natural Cancer Treatment That Matte MostEnvita Natural Medical Center in its Mexico office is currently utilizing NK cells andCTLs as immunotherapy Treatment for colon cancer and stage 4 cancer patients.Envitas proprietary immune therapy vaccine is called AAIT (for autologous adoptiveimmune therapy,) and there are 4 major cell types involved - the great majority beingnatural killer cells and T cells. The types of cells that make up Envitas treatment arelisted below:• Natural killer cells• Natural killer T cells• Cytokine-induced killer cells• Cytotoxic T lymphocytes
  5. 5. The vaccine(s) is compiled by growing a patient’s own antitumor immune cells into thebillions. These cells are then analyzed for activation markers and tested for their abilityto kill colon cancer and other stage 4 cancer cells in the laboratory, then re-infused intothe patient.Enhancing the immune system is a major benefit to fighting colon cancer or othercancers, but this vaccine-driven immunotherapy routine may be added upon throughsubtraction. Simply put, we can improve results by not only bolstering criticalcomponents of the immune system, but simultaneously depleting it of negative factorsthat impede its functionality. Depleting such negative factors is critical to a patientssuccess.It is no secret that cancer cells effect the release of T-regulatory cells, or "negative Tcells." The numbers of these cells correlate directly with specific cancer stages -respective to each cancer type. The more advanced the cancer, the higher the T-regulatory cells. These cells block your body’s system ability to fight. The immunesystem is the first and last defense against cancer.Naturally, by stepping in and acting to deplete these cells along with other key enzymesthat block critical immune system, cancer cell-killing action will be expeditedexponentially. Imagine your immune system being targeted and ready to go, yetsomething in your body suddenly applies the brakes. This is in fact what most advancedcolon cancer and stage 4 cancer patients are dealing with in regards to high regulatoryT cells. Envitas immunotherapy treatment protocols build a targeted vaccine by usingthe bodys most powerful cancer killers, but also depletes the portion of the immunesystem that inhibits the body from functioning efficiently in such regard.Case in point, there is no treatment (conventional or alternative) that can be effective inthe later stages of cancer if these negative T-cells are not effectively down-regulated.Unlike other available immunotherapy treatments, Envita’s AAIT can be used as astand-alone. AAIT can also be given in conjunction with other therapies that will act toenhance the effects of cells once they are in the patient. This is a key improvement overmany of the published studies in the scientific literature. Envita’s AAIT therapy is not justfocused on expanding cells in the laboratory; the ultimate goal is to also expand themand keep them activated after they are infused back into the body. Making AAIT nextimportant piece to colon cancer and stage 4 cancer therapy.AAIT Immunology Available for Stage 4 Colon cancer and Stage 4 CancerPatients at Envita Mexico Leader in Alternative Cancer Treatment and NaturalCancer TreatmentEnvita Natural Medical Center is currently utilizing NK, NKT, and T lymphocytes assupportive immunotherapy for our cancer patients. Envita’s therapy is titled AAIT, andincreases a patient’s own antitumor immune cells into the billions over a span of severalweeks. These cells are monitored for activation markers, evaluated for their ability to kill
  6. 6. cancer cells in the laboratory, and then subsequently re-infused into the patient.Heralded by scientific research and clinical results, Enivtas AAIT immunotherapy offersa potent option for cancer patients who are dedicated to battling stage 4 colon and otherstage 4 cancers while maintaining an intact immune system. Envita administers onlysuperior combinations of conventional and alternative cancer treatment bolstered byadvanced natural cancer treatment to help patients get healthier and improve theiroverall quality of life.1. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance ofnatural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987Nov;122(11):1264-8.2. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granularlymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg.1983 Aug;198(2):192-9.3. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M.Preoperative natural killer cell activity as a prognostic factor for distant metastasisfollowing surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.3. Matsunaga H, Kuwahara Y, Kusugami K, Morise K, Shimokata K. Natural killer,lymphokine-activated killer and interferon-gamma producing activities of peripheralblood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.Gastroenterol Jpn. 1988 Oct; 23(5):527-33.4. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M.Preoperative natural killer cell activity as a prognostic factor for distant metastasisfollowing surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.5. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE.Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinomapatients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003 Jul10;105(5):717-23.6. Waller CA, Gill PG, MacLennan IC. Enhancement of lymphocyte-mediatedcytotoxicity after tumor resection in patients with colorectal cancer. J Natl Cancer Inst.1980 Aug;65(2):223-30.

×